Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Mesothelioma × dostarlimab × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 9 Neoplasms 4 Lung Neoplasms 3 Neoplasm Metastasis 2 Melanoma 2 Colorectal Neoplasms 2 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Mesothelioma, Malignant 1 Mesothelioma 1 Head and Neck Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Neuroendocrine 1 Breast Neoplasms 1

Interventions

Pemetrexed 35 Cisplatin 30 pembrolizumab 19 Nivolumab 15 Carboplatin 15 Ipilimumab 11 Gemcitabine 9 Cyclophosphamide 7 durvalumab 6 fludarabine 5 Bevacizumab 5 Radiotherapy, Intensity-Modulated 4 Dexamethasone 4 tremelimumab 3 tazemetostat 3 olaparib 3 niraparib 3 anetumab ravtansine 3 Vinorelbine 3 Paclitaxel 3 LMB-100 3 Imatinib Mesylate 3 Fluorouracil 3 Cerebral Decortication 3 Blood Specimen Collection 3 sargramostim 2 fludarabine phosphate 2 defactinib 2 budigalimab 2 belinostat 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04940637 2023-05-12

UNITO-001

University of Turin, Italy

Phase 2 Unknown

Other solid neoplasmThoracic

Lung Neoplasms, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡